Evidence map›Paper›PMID 31779498›Full record

ArticleInnate immunity2020

Luzindole attenuates LPS/d-galactosamine-induced acute hepatitis in mice.

Yisheng Luo, Yongqiang Yang, Yi Shen, Longjiang Li, Jiayi Huang, Li Tang, Li Zhang

Open access · goldAbstract read
In one paragraph

Article in Innate immunity, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.9field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Macrophage pathology in hepatotoxicity.Journal of toxicologic pathology · 2023
    Review
  2. Article
  3. Article
  4. Article
  5. Antioxidant and Anti-Inflammatory Effects ofAntioxidants (Basel, Switzerland) · 2021
    Article
  6. Acute blockade of endogenous melatonin by Luzindole, with or without peripheral LPS injection, induces jejunal inflammation and morphological alterations in Swiss mice.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2021
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Yisheng LuoDepartment of Pathophysiology, Chongqing Medical University, PR China.ORCID 0000-0001-5770-7275
Yongqiang YangDepartment of Pathophysiology, Chongqing Medical University, PR China.ORCID 0000-0003-2048-8309
Yi ShenDepartment of Pathophysiology, Chongqing Medical University, PR China.
Longjiang LiDepartment of Pathophysiology, Chongqing Medical University, PR China.
Jiayi HuangDepartment of Pathophysiology, Chongqing Medical University, PR China.
Li TangDepartment of Pathophysiology, Chongqing Medical University, PR China.
Li ZhangDepartment of Pathophysiology, Chongqing Medical University, PR China.
Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Melatonin is a well-documented hormone that plays central roles in the regulation of sleep-wake cycles. There is cumulative evidence to suggest that melatonin is also a pleiotropic regulator of inflammation, and luzindole has been widely used as a melatonin receptor antagonist. This study investigated the potential effects of luzindole on LPS/d-galactosamine (d-GalN)-induced acute hepatitis. The results indicated that treatment with luzindole alleviated histological damage in the liver, reduced the level of transaminases in plasma and improved the survival of LPS/d-GalN-exposed mice. Treatment with luzindole also suppressed the production of the pro-inflammatory cytokines TNF-α and IL-6 in LPS/d-GalN-exposed mice. In addition, treatment with luzindole inhibited the activation of caspase-3, -8 and -9, and suppressed the cleavage of caspase-3 and poly(ADP-ribose) polymerase. Therefore, treatment with luzindole attenuates LPS/d-GalN-induced acute liver injury, suggesting that luzindole might have potential value for the intervention of inflammation-based hepatic disorders.

Indexed as

Acute DiseaseAnimalsAnti-Inflammatory AgentsApoptosisDisease Models, AnimalGalactosamineHepatitisHumansInterleukin-6LipopolysaccharidesLiverMelatoninMiceMice, Inbred BALB CReceptors, MelatoninTryptaminesAnti-Inflammatory AgentsGalactosamineInterleukin-6LipopolysaccharidesluzindoleMelatoninReceptors, MelatoninTryptaminesTumor Necrosis Factor-alphaacute liver injuryapoptosisinflammationluzindoleMelatonin

Identifiers

PMID31779498
PMCPMC7251793
OpenAlexW2990750510

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.